Free tool
FAERS Monitor: Steglatro
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 209803 or its brand name (Steglatro, Ertugliflozin). Reports on generic versions are filed under their own applications.
Reports
1,116
Serious
520
47% of reports
Hospitalization
328
Death reported
12
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- nausea91
- product dose omission issue71
- urinary tract infection66
- vomiting65
- fungal infection58
- no adverse event56
- diabetic ketoacidosis54
- blood glucose increased51
- dizziness49
- diarrhoea47
- drug ineffective41
- product dose omission29
- decreased appetite28
- diabetes mellitus inadequate control28
- fatigue26
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2013 | 1 |
| 2017 | 2 |
| 2018 | 132 |
| 2019 | 280 |
| 2020 | 95 |
| 2021 | 81 |
| 2022 | 96 |
| 2023 | 112 |
| 2024 | 116 |
| 2025 | 125 |
| 2026 | 76 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,043 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| diabetic ketoacidosisSignal | 54 | 42.5 | 32.7 | 2,143 |
| fungal infectionSignal | 58 | 32.9 | 25.6 | 1,759 |
| diabetes mellitus inadequate controlSignal | 28 | 29.9 | 20.7 | 752 |
| product dose omissionSignal | 29 | 8.4 | 5.8 | 182 |
| urinary tract infectionSignal | 66 | 7.3 | 5.8 | 355 |
| no adverse eventSignal | 56 | 5.8 | 4.5 | 221 |
| blood glucose increasedSignal | 51 | 5.1 | 3.9 | 166 |
| product dose omission issueSignal | 71 | 4.6 | 3.6 | 196 |
| vomitingSignal | 65 | 2.6 | 2.1 | 64 |
| decreased appetiteSignal | 28 | 2.3 | 1.6 | 19 |
| nauseaSignal | 91 | 2.2 | 1.8 | 58 |
| dizziness | 49 | 1.9 | 1.4 | 19 |
| diarrhoea | 47 | 1.4 | 1.0 | 5 |
| fatigue | 26 | 0.6 | 0.4 | 6 |
| drug ineffective | 41 | 0.6 | 0.4 | 12 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.